When it comes to cancer drugs, the US Food and Drug Administration is willing to go where other regulators are not. A new study found that the FDA has granted accelerated review and approval to dozens of cancer drugs that were either not reviewed or denied authorisation by NICE and/or the European Medicines Agency (EMA), ...
Why the FDA’s ‘fast track’ approval process may be hindering cancer therapy around the world
By Dave Levitan
25 Feb 2021